1. Effect of rosiglitazone on in vitro pre-implantation mouse embryo development
Fariborz Moghaddam1,2, Mehdi Hajian1, Shiva Rouhollahi 1 and Mohammad Hossein Nasr-Esfahani1
Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
Department of Biology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.
 Objectives
Results
Results
10 µM rosiglitazone caused the highest cleavage (% 100) and blastocyst (% ) rates.
Also, there is no significant difference in the total cell number between control and rosiglitazone groups.
Rosiglitazone as an anti-diabetic drugs has anti-inflammatory and anticancer properties. Rosiglitazone are highly selective and potent agonists for the nuclear receptor Peroxisome proliferator-activated receptor gamma (PPARγ), strongly implicated in female reproduction. Rosiglitazone have been proposed to exert anti-inflammatory effects because they may be inhibit secretion pro-inflammatory cytokines such as tumor necrosis factor-𝛼 (TNF- 𝛼) and interleukin 6. This study aimed to investigate the effect of rosiglitazone on in vitro pre-implantation mouse embryo development.
Conclusions
Methods
6-8 weeks female NMRI mice were superovulated with PMSG by intraperitoneal injection, followed by HCG injection after 48 hours. Mice were killed via cervical dislocation 18 hours post HCG injection after mate embryo were then recovered from oviduct ampulla and cultured with and without rosiglitazone (0, 10, 25, 50, 75 µM). Cleavage and blastocyst rate were assessed. Also, total cell number were assessed with differential staining.
These data provide evidence that blastocyst quantity and quality improved in embryos treated with rosiglitazone (10,25 µM) but no significant difference with control and groups of (50,75 µM) significant difference with control and Toxically that indicates PPAR𝛾 is a key target for embryo development.